Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| EBRO FOODS | - | 3 | +0,57 % | ||
| ENCE ENERGIA | - | 3 | +0,68 % | ||
| VIDRALA | - | 3 | +2,05 % | ||
| CIE AUTOMOTIVE | - | 3 | +0,21 % | ||
| PHARMAMAR | - | 2 | +1,10 % | ||
| TUBACEX | - | 1 | +0,36 % | ||
| ALMIRALL | - | 1 | +1,07 % | ||
| CAF | - | 1 | +1,64 % | ||
| ELECNOR | - | 1 | +1,80 % | ||
| NEINOR HOMES | - | 1 | +0,14 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ELECNOR, S.A.: Complementary Dividend for fiscal year 2024 and relevant dates | 4 | CNMV | ||
| Mi | ALMIRALL, S.A.: Information on dividend | 2 | CNMV | ||
| Di | PharmaMar präsentiert auf der ASCO dass Zepzelca® (lurbinectedin) in Kombination mit Atezolizumab (Tecentriq®) das Überleben als Erstlinien-Erhaltungstherapie bei kleinzelligem Lungenkrebs | 204 | news aktuell-CH | Madrid (ots/PRNewswire) - - Die Erstlinien-Erhaltungskombinationstherapie verringerte das Risiko eines Fortschreitens der Krankheit oder des Todes um 46%, mit einer medianen Gesamtüberlebenszeit von... ► Artikel lesen | |
| Di | PHARMA MAR, S.A.: Pharma Mar presents in ASCO positive results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer. | 5 | CNMV | ||
| Di | PharmaMar presents at ASCO that the Zepzelca(lurbinectedin) and atezolizumab (Tecentriq) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer | 220 | PR Newswire | First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from... ► Artikel lesen | |
| Mo | PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 26 May and 30 May 2025. | 2 | CNMV | ||
| Mo | EDREAMS ODIGEO, S.A.: The Company informs of the transactions carried out over its own shares under the Buy-back Program. | 1 | CNMV | ||
| Mo | ERCROS, S.A.: The Company sends a press release on the Board's supplementary report | 4 | CNMV | ||
| Mo | ERCROS, S.A.: The Company sends the supplementary report of the Board os Directors on the justification of the proposal to vote against the call supplement | 1 | CNMV |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .